30
Glomerulonefrite Membranosa Alvimar Gonçalves Delgado Serviço e Disciplina de Nefrologia - HUCFF Faculdade de Medicina UNIVERSIDADE FEDERAL DO RIO DE JANEIRO

*1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

  • Upload
    others

  • View
    5

  • Download
    0

Embed Size (px)

Citation preview

Page 1: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Glomerulonefrite Membranosa

Alvimar Gonçalves Delgado

Serviço e Disciplina de Nefrologia - HUCFFFaculdade de Medicina

UNIVERSIDADE FEDERAL DO RIO DE JANEIRO

Page 2: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Glomerulonefrite membranosa

1. Uma das principais causas de síndrome nefrótica em adultos

2. 80% dos casos são do tipo idiopático (?) e cerca de 20% são secundários a várias doenças, dentre elas:a. Lupus e Sarcoidoseb. Hepatite B e Cc. Esquistossomose (no Brasil)d. Neoplasias, Tiroiditee. Drogas (AINES, ouro coloidal, captopril,

penicilamina)

Page 3: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

GN IDIOPÁTICA: Presença de Ac IgG4 (70-80%) anti-PLA2R

Page 4: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 5: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 6: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Kriz, W and Elger, M

Page 7: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Anti-PLA2R50-80%

Glomerulonefrite membranosa primária

Page 8: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Anti-THSD7A3-9%

Anti-PLA2R50-80%

Glomerulonefrite membranosa primária

Page 9: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 10: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 11: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 12: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 13: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 14: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Depósitos granulares de IgGem alças capilares.

Page 15: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 16: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

J Am Soc Nephrol 2016

MO IgG C3

C1q PLRA2 ME

De Vriese AS, Glassock RJ, Nath KA, Sethi S and Fervenza FC.

GNM Anti-PLA2R

Page 17: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

IgG C3 PLRA2

IgG C3 PLRA2

A, B e C: GNM Anti-PLA2R positivoD, E e F: GNM Anti-PLA2R negativo

J Am Soc Nephrol 2016

De Vriese AS, Glassock RJ, Nath KA, Sethi S and Fervenza FC.

Page 18: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

J Am Soc Nephrol 2016De Vriese AS, Glassock RJ, Nath KA, Sethi S and Fervenza FC.

GNM Secundária

Page 19: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Apresentação clínica:

1. Início insidioso2. Proteinúria maciça em mais de 80%dos casos 2. Maioria apresenta síndrome nefrótica

Proteinúria > 3,5 g/24 hHipoalbuminemiaHipercolesterolemiaEdema generalizado

3. Alguns têm proteinúria assintomática 4. Muitos pacientes têm hematúria microscópica5. Evolução: regra dos 3 terços:

1/3 evolui para IRCT em poucos anos1/3 tem proteinúria persistente sem IRCT1/3 regride (às vezes espontaneamente)

Page 20: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Catran DC, JASN 2005

Page 21: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Catran, DC and Brenchley, PE. Kidney Int. 2016

Page 22: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

História natural da GNMi

Page 23: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 24: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Clorambucil e ciclofosfamida sãoigualmente eficazes

RC = 47%RP = 19%

Page 25: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Rituximab in Membranous Nephropathy

CP1125840-1

Proteinuria (g/24 hr)

Proteinuria (g/24 hr)

Serum creatinine (mg/dL)

Serum creatinine (mg/dL)

* P<0.01 vs months -6 and 0Ruggenenti et al: JASN 14:851, 2003

* P<0.01 vs months -6 and 0Ruggenenti et al: JASN 14:851, 2003

-6 0 3 6 9 12

MonthsMonths

**

**** **

****

Page 26: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 27: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 28: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv
Page 29: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

CP1313718-3

Relative Changes of Plasma Albumin Concentration and Urinary Proteins Excretion Induced by Short-Term ACTH Treatment in

14 Nephrotic Patients with Idiopathic Membranous Nephropathy%

of

init

ial l

evel

% o

f in

itia

l lev

el

DaysDaysBerg et al: KI 56:1534, 1999Berg et al: KI 56:1534, 1999

ACTH injectionsACTH injections

AlbuminU-1MAlbuminuriaIgG

Page 30: *1 ,',23È7,&$ 3UHVHQoD GH $F ,J* DQWL 3/$ 5sonerj.org.br/wp-content/uploads/2017/05/... · *orphuxorqhiulwhphpeudqrvd 8pd gdv sulqflsdlv fdxvdv gh vtqgurph qhiuywlfdhp dgxowrv grv

Catran, DC and Brenchley, PE. Kidney Int. 2016